The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessing global disparities in clinical trial availability for renal cell carcinoma (RCC).
 
Regina Barragan-Carrillo
No Relationships to Disclose
 
Miguel Zugman
No Relationships to Disclose
 
Daniela Castro
No Relationships to Disclose
 
Xiaochen Li
No Relationships to Disclose
 
Koral Shah
No Relationships to Disclose
 
Lily Lau
No Relationships to Disclose
 
Ruchi Agarwal
No Relationships to Disclose
 
Aaron Lee
No Relationships to Disclose
 
Skylar Reid
No Relationships to Disclose
 
Nasr Chaudhary
No Relationships to Disclose
 
Shivanee Kooner
No Relationships to Disclose
 
Salvador Jaime-Casas
No Relationships to Disclose
 
Hedyeh Ebrahimi
No Relationships to Disclose
 
Gabriela Regalado Porras
No Relationships to Disclose
 
Sharon Choi
No Relationships to Disclose
 
Nora Sobrevilla
No Relationships to Disclose
 
Erika Ruiz-Garcia
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BMS; Merck Serono; Roche/Genentech; SERVIER
Travel, Accommodations, Expenses - Gilead Sciences
 
Rana McKay
Consulting or Advisory Role - Ambrx; Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)
 
Sumanta Pal
Speakers' Bureau - IntrinsiQ; MJH Life Sciences; Peerview
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen